Leung AA, Pasieka JL, Hyrcza MD, Pacaud D, Dong Y, Boyd JM, et al. Epidemiology of pheochromocytoma and paraganglioma: population-based cohort study. Eur J Endocrinol. 2021;184:19–28.
CAS
PubMed
Google Scholar
Rodriguez-Cuevas H, Lau I, Rodriguez HP. High-altitude paragangliomas diagnostic and therapeutic considerations. Cancer. 1986;57:672–6.
CAS
PubMed
Google Scholar
Berends AMA, Buitenwerf E, de Krijger RR, Veeger N, van der Horst-Schrivers ANA, Links TP, et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review. Eur J Intern Med. 2018;51:68–73.
PubMed
Google Scholar
Lack EE, Cubilla AL, Woodruff JM, Farr HW. Paragangliomas of the head and neck region: a clinical study of 69 patients. Cancer. 1977;39:397–409.
CAS
PubMed
Google Scholar
Lloyd RV, Osamura YR, Kloppel G, Rosai J. WHO classification of tumours of endocrine organs. Geneva: WHO Press; 2017.
Google Scholar
Waguespack SG, Rich T, Grubbs E, Ying AK, Perrier ND, Ayala-Ramirez M, et al. A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2010;95:2023–37.
CAS
PubMed
Google Scholar
Pamporaki C, Hamplova B, Peitzsch M, Prejbisz A, Beuschlein F, Timmers H, et al. Characteristics of pediatric vs adult pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2017;102:1122–32.
PubMed
PubMed Central
Google Scholar
Curras-Freixes M, Pineiro-Yanez E, Montero-Conde C, Apellaniz-Ruiz M, Calsina B, Mancikova V, et al. PheoSeq: a targeted next-generation sequencing assay for pheochromocytoma and paraganglioma diagnostics. J Mol Diagn. 2017;19:575–88.
CAS
PubMed
PubMed Central
Google Scholar
Turchini J, Cheung VKY, Tischler AS, De Krijger RR, Gill AJ. Pathology and genetics of phaeochromocytoma and paraganglioma. Histopathology. 2018;72:97–105.
PubMed
Google Scholar
Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, Pacak K, et al. The North American neuroendocrine tumor society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39:775–83.
PubMed
PubMed Central
Google Scholar
Jochmanova I, Abcede AMT, Guerrero RJS, Malong CLP, Wesley R, Huynh T, et al. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. J Cancer Res Clin Oncol. 2020;146:1051–63.
CAS
PubMed
PubMed Central
Google Scholar
Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915–42.
CAS
PubMed
Google Scholar
Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007;92:3822–8.
CAS
PubMed
Google Scholar
Hescot S, Curras-Freixes M, Deutschbein T, van Berkel A, Vezzosi D, Amar L, et al. Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): a European network for the study of adrenal tumors retrospective study. J Clin Endocrinol Metab. 2019;104:2367–74.
PubMed
Google Scholar
Cascón A, Remacha L, Calsina B, Robledo M. Pheochromocytomas and paragangliomas: bypassing cellular respiration. Cancers. 2019;11:683.
PubMed Central
Google Scholar
Goffredo P, Sosa JA, Roman SA. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades. J Surg Oncol. 2013;107:659–64.
PubMed
Google Scholar
Oudijk L, de Krijger RR, Pacak K, Tischler AS. Adrenal medulla and extra-adrenal paraganglia. In: Mete O, Asa SL, editors. Endocrine pathology. Cambridge: Cambridge University Press; 2016. p. 628–76.
Google Scholar
Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001;86:5210–6.
CAS
PubMed
Google Scholar
Thompson LD. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002;26:551–66.
PubMed
Google Scholar
Kimura N, Watanabe T, Noshiro T, Shizawa S, Miura Y. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol. 2005;16:23–32.
PubMed
Google Scholar
Curras-Freixes M, Inglada-Perez L, Mancikova V, Montero-Conde C, Leton R, Comino-Mendez I, et al. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients. J Med Genet. 2015;52:647–56.
CAS
PubMed
Google Scholar
Papathomas TG, Oudijk L, Persu A, Gill AJ, van Nederveen F, Tischler AS, et al. SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a multinational study of the European network for the study of adrenal tumors (ENS@T). Mod Pathol. 2015;28:807–21.
CAS
PubMed
Google Scholar
Pierre C, Agopiantz M, Brunaud L, Battaglia-Hsu SF, Max A, Pouget C, et al. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas. Virchows Arch. 2019;474:721–34.
CAS
PubMed
Google Scholar
Jimenez C, Libutti SK, Landry CS, Lloyd RV, McKay RR, Rohren E, et al. Adrenal-neuroendocrine tumors. In: Mete O, Asa S, editors., et al., AJCC cancer staging manual. New York: Springer; 2017. p. 919–27.
Google Scholar
Langerman A, Athavale SM, Rangarajan SV, Sinard RJ, Netterville JL. Natural history of cervical paragangliomas: outcomes of observation of 43 patients. Arch Otolaryngol Head Neck Surg. 2012;138:341–5.
PubMed
Google Scholar
Amato B, Bianco T, Compagna R, Siano M, Esposito G, Buffone G, et al. Surgical resection of carotid body paragangliomas: 10 years of experience. Am J Surg. 2014;207:293–8.
PubMed
Google Scholar
Lima J, Feijao T, da Silva AF, Pereira-Castro I, Fernandez-Ballester G, Maximo V, et al. High frequency of germline succinate dehydrogenase mutations in sporadic cervical paragangliomas in northern Spain: mitochondrial succinate dehydrogenase structure-function relationships and clinical-pathological correlations. J Clin Endocrinol Metab. 2007;92:4853–64.
CAS
PubMed
Google Scholar
Burnichon N, Abermil N, Buffet A, Favier J, Gimenez-Roqueplo AP. The genetics of paragangliomas. Eur Ann Otorhinolaryngol Head Neck Dis. 2012;129:315–8.
CAS
PubMed
Google Scholar
Gimenez-Roqueplo AP, Dahia PL, Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res. 2012;44:328–33.
CAS
PubMed
Google Scholar
Kantorovich V, Pacak K. New insights on the pathogenesis of paraganglioma and pheochromocytoma. F1000Res. 2018;7:F1000 Faculty Rev–500.
Google Scholar
Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet. 2010;42:229–33.
CAS
PubMed
PubMed Central
Google Scholar
Burnichon N, Cascon A, Schiavi F, Morales NP, Comino-Mendez I, Abermil N, et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res. 2012;18:2828–37.
CAS
PubMed
Google Scholar
Castro-Vega LJ, Buffet A, De Cubas AA, Cascon A, Menara M, Khalifa E, et al. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum Mol Genet. 2014;23:2440–6.
CAS
PubMed
Google Scholar
Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31:181–93.
CAS
PubMed
PubMed Central
Google Scholar
Remacha L, Pirman D, Mahoney CE, Coloma J, Calsina B, Currás-Freixes M, et al. Recurrent germline DLST mutations in individuals with multiple pheochromocytomas and paragangliomas. Am J Hum Genet. 2019;104:1008–10.
CAS
PubMed
PubMed Central
Google Scholar
Buffet A, Morin A, Castro-Vega LJ, Habarou F, Lussey-Lepoutre C, Letouzé E, et al. Germline mutations in the mitochondrial 2-oxoglutarate/malate carrier SLC25A11 gene confer a predisposition to metastatic paragangliomas. Cancer Res. 2018;78:1914–22.
CAS
PubMed
Google Scholar
Alrezk R, Suarez A, Tena I, Pacak K. Update of pheochromocytoma syndromes: genetics, biochemical evaluation, and imaging. Front Endocrinol (Lausanne). 2018;9:515.
PubMed Central
Google Scholar
Bernardo-Castiñeira C, Valdés N, Celada L, Martinez ASJ, Sáenz-de-Santa-María I, Bayón GF, et al. Epigenetic deregulation of protocadherin PCDHGC3 in pheochromocytomas/paragangliomas associated with SDHB mutations. J Clin Endocrinol Metab. 2019;104:5673–92.
PubMed
Google Scholar
Lopez-Jimenez E, Gomez-Lopez G, Leandro-Garcia LJ, Munoz I, Schiavi F, Montero-Conde C, et al. Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol. 2010;24:2382–91.
CAS
PubMed
PubMed Central
Google Scholar
Kimura N, Miura Y, Nagatsu I, Nagura H. Catecholamine synthesizing enzymes in 70 cases of functioning and non-functioning phaeochromocytoma and extra-adrenal paraganglioma. Virchows Arch A Pathol Anat Histopathol. 1992;421:25–32.
CAS
PubMed
Google Scholar
Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol. 1992;147:1–10.
CAS
PubMed
Google Scholar
Lam AK. Update on adrenal tumours in 2017 world health organization (WHO) of endocrine tumours. Endocr Pathol. 2017;28:213–27.
PubMed
Google Scholar
Parikh PP, Rubio GA, Farra JC, Lew JI. Nationwide review of hormonally active adrenal tumors highlights high morbidity in pheochromocytoma. J Surg Res. 2017;215:204–10.
CAS
PubMed
Google Scholar
Zhang R, Gupta D, Albert SG. Pheochromocytoma as a reversible cause of cardiomyopathy: analysis and review of the literature. Int J Cardiol. 2017;249:319–23.
PubMed
Google Scholar
Else T, Greenberg S, Fishbein L. Hereditary paraganglioma-pheochromocytoma syndromes. In: Adam M, Ardinger H, Pagon R, editors. GeneReviews. Seattle: University of Washington; 2018. p. 1993–2020.
Google Scholar
Geroula A, Deutschbein T, Langton K, Masjkur J, Pamporaki C, Peitzsch M, et al. Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. Eur J Endocrinol. 2019;181:409–20.
CAS
PubMed
Google Scholar
Neumann HPH, Young WF, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med. 2019;381:552–65.
CAS
PubMed
Google Scholar
Nolting S, Ullrich M, Pietzsch J, Ziegler CG, Eisenhofer G, Grossman A, et al. Current management of pheochromocytoma/paraganglioma: a guide for the practicing clinician in the era of precision medicine. Cancers (Basel). 2019;11:1505.
Google Scholar
Crona J, Taieb D, Pacak K. New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification. Endocr Rev. 2017;38:489–515.
PubMed
PubMed Central
Google Scholar
Castro-Vega LJ, Letouze E, Burnichon N, Buffet A, Disderot PH, Khalifa E, et al. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun. 2015;6:6044.
CAS
PubMed
Google Scholar
Jochmanova I, Pacak K. Genomic landscape of pheochromocytoma and paraganglioma. Trends Cancer. 2018;4:6–9.
CAS
PubMed
Google Scholar
Valdés N, Navarro E, Mesa J, Casterás A, Alcázar V, Lamas C, et al. RET Cys634Arg mutation confers a more aggressive multiple endocrine neoplasia type 2A phenotype than Cys634Tyr mutation. Eur J Endocrinol. 2015;172:301–7.
PubMed
Google Scholar
van der Harst E, de Herder WW, de Krijger RR, Bruining HA, Bonjer HJ, Lamberts SW, et al. The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol. 2002;147:85–94.
PubMed
Google Scholar
Eisenhofer G, Lenders JW, Goldstein DS, Mannelli M, Csako G, Walther MM, et al. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem. 2005;51:735–44.
CAS
PubMed
Google Scholar
Righini C, Pecher M, Halimi S, Magne JL, Reyt E. Malignant carotid paraganglioma. A case report. Ann Otolaryngol Chir Cervicofac. 2003;120:103–8.
PubMed
Google Scholar
van Duinen N, Corssmit EP, de Jong WH, Brookman D, Kema IP, Romijn JA. Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24-h urinary excretion rates of catecholamines and metabolites. Eur J Endocrinol. 2013;169:377–82.
PubMed
Google Scholar
Pacak K, Eisenhofer G, Ilias I. Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. Hormones (Athens). 2009;8:111–6.
Google Scholar
Van der Horst-Schrivers AN, Osinga TE, Kema IP, Van der Laan BF, Dullaart RP. Dopamine excess in patients with head and neck paragangliomas. Anticancer Res. 2010;30:5153–8.
Google Scholar
Eisenhofer G, Lenders JW, Timmers H, Mannelli M, Grebe SK, Hofbauer LC, et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem. 2011;57:411–20.
CAS
PubMed
PubMed Central
Google Scholar
Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292:943–51.
CAS
PubMed
Google Scholar
Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23:8812–8.
CAS
PubMed
Google Scholar
Jha A, de Luna K, Balili CA, Millo C, Paraiso CA, Ling A, et al. Clinical, diagnostic, and treatment characteristics of SDHA-related metastatic pheochromocytoma and paraganglioma. Front Oncol. 2019;9:53.
PubMed
PubMed Central
Google Scholar
Neary NM, King KS, Pacak K. Drugs and pheochromocytoma–don’t be fooled by every elevated metanephrine. N Engl J Med. 2011;364:2268–70.
CAS
PubMed
PubMed Central
Google Scholar
Weise M, Merke DP, Pacak K, Walther MM, Eisenhofer G. Utility of plasma free metanephrines for detecting childhood pheochromocytoma. J Clin Endocrinol Metab. 2002;87:1955–60.
CAS
PubMed
Google Scholar
Casey R, Griffin TP, Wall D, Dennedy MC, Bell M, O’Shea PM. Screening for phaeochromocytoma and paraganglioma: impact of using supine reference intervals for plasma metanephrines with samples collected from fasted/seated patients. Ann Clin Biochem. 2017;54:170–3.
CAS
PubMed
Google Scholar
Darr R, Kuhn M, Bode C, Bornstein SR, Pacak K, Lenders JWM, et al. Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. Endocrine. 2017;56:495–503.
PubMed
PubMed Central
Google Scholar
Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab. 2003;88:2656–66.
CAS
PubMed
Google Scholar
van Berkel A, Lenders JW, Timmers HJ. Diagnosis of endocrine disease: biochemical diagnosis of phaeochromocytoma and paraganglioma. Eur J Endocrinol. 2014;170:R109–19.
PubMed
Google Scholar
van Berkel A, Rao JU, Kusters B, Demir T, Visser E, Mensenkamp AR, et al. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma. J Nucl Med. 2014;55:1253–9.
PubMed
Google Scholar
Lenders JW, Pacak K, Huynh TT, Sharabi Y, Mannelli M, Bratslavsky G, et al. Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma. J Clin Endocrinol Metab. 2010;95:238–45.
CAS
PubMed
Google Scholar
Olson SW, Yoon S, Baker T, Prince LK, Oliver D, Abbott KC. Longitudinal plasma metanephrines preceding pheochromocytoma diagnosis: a retrospective case-control serum repository study. Eur J Endocrinol. 2016;174:289–95.
CAS
PubMed
Google Scholar
Algeciras-Schimnich A, Preissner CM, Young WF, Singh RJ, Grebe SK. Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab. 2008;93:91–5.
CAS
PubMed
Google Scholar
Rao D, Peitzsch M, Prejbisz A, Hanus K, Fassnacht M, Beuschlein F, et al. Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. Eur J Endocrinol. 2017;177:103–13.
CAS
PubMed
PubMed Central
Google Scholar
Ctvrtlik F, Koranda P, Schovanek J, Skarda J, Hartmann I, Tudos Z. Current diagnostic imaging of pheochromocytomas and implications for therapeutic strategy. Exp Ther Med. 2018;15:3151–60.
CAS
PubMed
PubMed Central
Google Scholar
Rogowski-Lehmann N, Geroula A, Prejbisz A, Timmers H, Megerle F, Robledo M, et al. Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging. Endocr Connect. 2018;7:1168–77.
CAS
PubMed Central
Google Scholar
Havekes B, King K, Lai EW, Romijn JA, Corssmit EP, Pacak K. New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf). 2010;72:137–45.
CAS
Google Scholar
Leung K, Stamm M, Raja A, Low G. Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. AJR Am J Roentgenol. 2013;200:370–8.
PubMed
Google Scholar
Sargar KM, Khanna G, Hulett BR. Imaging of nonmalignant adrenal lesions in children. Radiographics. 2017;37:1648–64.
PubMed
Google Scholar
Taieb D, Hicks RJ, Hindie E, Guillet BA, Avram A, Ghedini P, et al. European association of nuclear medicine practice guideline/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46:2112–37.
PubMed
PubMed Central
Google Scholar
Mercado-Asis LB, Wolf KI, Jochmanova I, Taieb D. Pheochromocytoma: a genetic and diagnostic update. Endocr Pract. 2018;24:78–90.
PubMed
Google Scholar
Pappachan JM, Raskauskiene D, Sriraman R, Edavalath M, Hanna FW. Diagnosis and management of pheochromocytoma: a practical guide to clinicians. Curr Hypertens Rep. 2014;16:442.
PubMed
Google Scholar
Carty SE, Young WF. Paragangliomas: epidemiology, clinical presentation, diagnosis and histology. UptoDate. 2018
Kan Y, Zhang S, Wang W, Liu J, Yang J, Wang Z. (68)Ga-somatostatin receptor analogs and (18)F-FDG PET/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis. Acta Radiol. 2018;59:1466–74.
PubMed
Google Scholar
Bessell-Browne R, O’Malley ME. CT of pheochromocytoma and paraganglioma: risk of adverse events with i.v. administration of nonionic contrast material. AJR Am J Roentgenol. 2007;188:970–4.
PubMed
Google Scholar
Weingarten TN, Welch TL, Moore TL, Walters GF, Whipple JL, Cavalcante A, et al. Preoperative levels of catecholamines and metanephrines and intraoperative hemodynamics of patients undergoing pheochromocytoma and paraganglioma resection. Urology. 2017;100:131–8.
PubMed
Google Scholar
Heslin MJ, Liles JS, Moctezuma-Velazquez P. The use of telemedicine in the preoperative management of pheochromocytoma saves resources. Mhealth. 2019;5:27.
PubMed
PubMed Central
Google Scholar
Berends AMA, Kerstens MN, Lenders JWM, Timmers H. Approach to the patient: perioperative management of the patient with pheochromocytoma or sympathetic paraganglioma. J Clin Endocrinol Metab. 2020;105:3088–102.
Google Scholar
Álvarez-Morujo RJG-O, Ruiz MÁA, Belisario JDC, Guirado TM, Yurrita BS. Head and neck paragangliomas: experience in 126 patients with 162 tumours. Acta Otorrinolaringol. 2015;66:332–41.
Google Scholar
Alvarez-Morujo RJ, Ruiz MA, Serafini DP, Delgado IL, Friedlander E, Yurrita BS. Management of multicentric paragangliomas: review of 24 patients with 60 tumors. Head Neck. 2016;38:267–76.
PubMed
Google Scholar
Shamblin WR, Reine WH, Sheps SG, Harrison EG. Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases. Am J Surg. 1971;122:732–9.
CAS
PubMed
Google Scholar
Prasad SC, Mimoune HA, Khardaly M, Piazza P, Russo A, Sanna M. Strategies and long-term outcomes in the surgical management of tympanojugular paragangliomas. Head Neck. 2016;38:871–85.
PubMed
Google Scholar
Shen WT, Grogan R, Vriens M, Clark OH, Duh QY. One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy. Arch Surg. 2010;145:893–7.
PubMed
Google Scholar
Rossitti HM, Soderkvist P, Gimm O. Extent of surgery for phaeochromocytomas in the genomic era. Br J Surg. 2018;105:e84-98.
CAS
PubMed
Google Scholar
Vidal O, Delgado-Oliver E, Diaz Del Gobbo R, Hanzu F, Squarcia M, Martinez D, et al. Functional adrenal cortex preservation: a good reason for posterior retroperitoneal endoscopic approach. Cir Esp. 2018;96:488–93.
PubMed
Google Scholar
Zarnegar R, Kebebew E, Duh QY, Clark OH. Malignant pheochromocytoma. Surg Oncol Clin N Am. 2006;15:555–71.
PubMed
Google Scholar
Heger P, Probst P, Huttner FJ, Goossen K, Proctor T, Muller-Stich BP, et al. Evaluation of open and minimally invasive adrenalectomy: a systematic review and network meta-analysis. World J Surg. 2017;41:2746–57.
PubMed
Google Scholar
Del Moral JMV, Gonzalez JMR, Llorente PM, Martinez JMM, Barrasate ADLQ, Rodriguez AE, et al. Adrenal surgery in Spain: final results of a national survey. Cir Esp. 2011;89:663–9.
Google Scholar
Walz MK, Alesina PF, Wenger FA, Koch JA, Neumann HP, Petersenn S, et al. Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients. World J Surg. 2006;30:899–908.
PubMed
Google Scholar
Conzo G, Tartaglia E, Gambardella C, Esposito D, Sciascia V, Mauriello C, et al. Minimally invasive approach for adrenal lesions: systematic review of laparoscopic versus retroperitoneoscopic adrenalectomy and assessment of risk factors for complications. Int J Surg. 2016;28(Suppl 1):S118–23.
PubMed
Google Scholar
Jansen TTG, Timmers H, Marres HAM, Kaanders J, Kunst HPM. Results of a systematic literature review of treatment modalities for jugulotympanic paraganglioma, stratified per Fisch class. Clin Otolaryngol. 2018;43:652–61.
CAS
PubMed
Google Scholar
Gigliotti MJ, Hasan S, Liang Y, Chen D, Fuhrer R, Wegner RE. A 10-year experience of linear accelerator-based stereotactic radiosurgery/radiotherapy (SRS/SRT) for paraganglioma: a single institution experience and review of the literature. J Radiosurg SBRT. 2018;5:183–90.
PubMed
PubMed Central
Google Scholar
Giammarile F, Chiti A, Lassmann M, Brans B, Flux G. EANM EANM procedure guidelines for 131I-meta-iodobenzylguanidine 131I-mIBG) therapy. Eur J Nucl Med Mol Imasging. 2008;35:1039–47.
CAS
Google Scholar
Kayano D, Kinuya S. Current consensus on I-131 MIBG therapy. Nucl Med Mol Imaging. 2018;52:254–65.
CAS
PubMed
PubMed Central
Google Scholar
Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, et al. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol. 2014;171:R111–22.
CAS
PubMed
Google Scholar
van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014;80:487–501.
Google Scholar
Carrasquillo JA, Pandit-Taskar N, Chen CC. I-131 metaiodobenzylguanidine therapy of pheochromocytoma and paraganglioma. Semin Nucl Med. 2016;46:203–14.
PubMed
Google Scholar
Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, et al. Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med. 2019;60:623–30.
CAS
PubMed
PubMed Central
Google Scholar
Kong G, Grozinsky-Glasberg S, Hofman MS, Callahan J, Meirovitz A, Maimon O, et al. Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma. J Clin Endocrinol Metab. 2017;102:3278–87.
PubMed
Google Scholar
Kolasinska-Cwikla A, Peczkowska M, Cwikla JB, Michalowska I, Palucki JM, Bodei L, et al. A clinical efficacy of PRRT in patients with advanced, nonresectable, paraganglioma-pheochromocytoma, related to SDHx gene mutation. J Clin Med. 2019;8:952.
CAS
PubMed Central
Google Scholar
Pang Y, Liu Y, Pacak K, Yang C. Pheochromocytomas and paragangliomas: from genetic diversity to targeted therapies. Cancers (Basel). 2019;11:436.
CAS
Google Scholar
Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer. 2012;118:2804–12.
CAS
PubMed
Google Scholar
Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014;81:642–51.
CAS
Google Scholar
Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer. 2014;135:2711–20.
CAS
PubMed
Google Scholar
Tena I, Gupta G, Tajahuerce M, Benavent M, Cifrian M, Falcon A, et al. Successful second-line metronomic temozolomide in metastatic paraganglioma: case reports and review of the literature. Clin Med Insights Oncol. 2018;12:1179554918763367.
PubMed
PubMed Central
Google Scholar
Pang Y, Lu Y, Caisova V, Liu Y, Bullova P, Huynh TT, et al. Targeting NAD(+)/PARP DNA repair pathway as a novel therapeutic approach to SDHB-mutated cluster I pheochromocytoma and paraganglioma. Clin Cancer Res. 2018;24:3423–32.
CAS
PubMed
PubMed Central
Google Scholar
O’Kane GM, Ezzat S, Joshua AM, Bourdeau I, Leibowitz-Amit R, Olney HJ, et al. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Br J Cancer. 2019;120:1113–9.
CAS
PubMed
PubMed Central
Google Scholar
Jasim S, Suman VJ, Jimenez C, Harris P, Sideras K, Burton JK, et al. Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma. Endocrine. 2017;57:220–5.
CAS
PubMed
Google Scholar
Pichun MEB, Edgerly M, Velarde M, Bates SE, Daerr R, Adams K, et al. Phase II clinical trial of axitinib in metastatic pheochromocytomas and paraganlgiomas (P/PG): preliminary results. J Clin Oncol. 2015;33:457.
Google Scholar
Hadoux J, Terroir M, Leboulleux S, Deschamps F, Al Ghuzlan A, Hescot S, et al. Interferon-alpha treatment for disease control in metastatic pheochromocytoma/paraganglioma patients. Horm Cancer. 2017;8:330–7.
CAS
PubMed
Google Scholar
Kohlenberg J, Welch B, Hamidi O, Callstrom M, Morris J, Sprung J, et al. Efficacy and safety of ablative therapy in the treatment of patients with metastatic pheochromocytoma and paraganglioma. Cancers (Basel). 2019;11:195.
CAS
Google Scholar
Kittah NE, Iñiguez-Ariza NM, Hamidi O, Tamhane S, Young WF Jr, Bancos I, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab. 2017;102:3296–305.
PubMed
PubMed Central
Google Scholar
Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JW, et al. European society of endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016;174:G1-10.
CAS
PubMed
Google Scholar
van den Broek PJ, de Graeff J. Prolonged survival in a patient with pulmonary metastases of a malignant pheochromocytoma. Neth J Med. 1978;21:245–7.
PubMed
Google Scholar
Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011;96:717–25.
CAS
PubMed
Google Scholar
King KS, Prodanov T, Kantorovich V, Fojo T, Hewitt JK, Zacharin M, et al. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol. 2011;29:4137–42.
CAS
PubMed
PubMed Central
Google Scholar
Schovanek J, Martucci V, Wesley R, Fojo T, Del Rivero J, Huynh T, et al. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study. BMC Cancer. 2014;14:523.
PubMed
PubMed Central
Google Scholar
Janssen I, Blanchet EM, Adams K, Chen CC, Millo CM, Herscovitch P, et al. Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res. 2015;21:3888–95.
CAS
PubMed
PubMed Central
Google Scholar
Muth A, Crona J, Gimm O, Elmgren A, Filipsson K, Stenmark Askmalm M, et al. Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. J Intern Med. 2019;285:187–204.
CAS
PubMed
Google Scholar
MacFarlane J, Seong KC, Bisambar C, Madhu B, Allinson K, Marker A, et al. A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: Beyond phaeochromocytoma and paraganglioma. Clin Endocrinol. 2020;93:528–38.
CAS
Google Scholar
Tufton N, Sahdev A, Drake WM, Akker SA. Can subunit-specific phenotypes guide surveillance imaging decisions in asymptomatic SDH mutation carriers? Clin Endocrinol (Oxf). 2019;90:31–46.
CAS
Google Scholar
Castinetti F, Waguespack SG, Machens A, Uchino S, Hasse-Lazar K, Sanso G, et al. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes Endocrinol. 2019;7:213–20.
PubMed
PubMed Central
Google Scholar
Casey R, Neumann HPH, Maher ER. Genetic stratification of inherited and sporadic phaeochromocytoma and paraganglioma: implications for precision medicine. Hum Mol Genet. 2020;29:R128–37.
CAS
PubMed
Google Scholar
Papathomas TG, Suurd DPD, Pacak K, Tischler AS, Vriens MR, Lam AK, et al. What have we learned from molecular biology of paragangliomas and pheochromocytomas? Endocr Pathol. 2021;32:134–53.
PubMed
Google Scholar
Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL. Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst. 2003;95:1196–204.
CAS
PubMed
Google Scholar
Müller U, Troidl C, Niemann S. SDHC mutations in hereditary paraganglioma/pheochromocytoma. Fam Cancer. 2005;4:9–12.
PubMed
Google Scholar
Bayley JP, Kunst HP, Cascon A, Sampietro ML, Gaal J, Korpershoek E, et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol. 2010;11:366–72.
CAS
PubMed
Google Scholar
Burnichon N, Brière JJ, Libé R, Vescovo L, Rivière J, Tissier F, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;19:3011–20.
CAS
PubMed
PubMed Central
Google Scholar
Gaal J, Burnichon N, Korpershoek E, Roncelin I, Bertherat J, Plouin PF, et al. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2010;95:1274–8.
CAS
PubMed
Google Scholar
Yao L, Barontini M, Niederle B, Jech M, Pfragner R, Dahia PLM. Mutations of the metabolic genes IDH1, IDH2, and SDHAF2 are not major determinants of the pseudohypoxic phenotype of sporadic pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2010;95:1469–72.
CAS
PubMed
PubMed Central
Google Scholar
Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, Landa I, Leandro-García LJ, Letón R, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet. 2011;43:663–7.
PubMed
Google Scholar
Clark GR, Sciacovelli M, Gaude E, Walsh DM, Kirby G, Simpson MA, et al. Germline FH mutations presenting with pheochromocytoma. J Clin Endocrinol Metab. 2014;99:E2046–50.
CAS
PubMed
Google Scholar
Gupta G, Pacak K, Aace Adrenal Scientific Committee. Precision medicine: an update on genotype/biochemical phenotype relationships in pheochromocytoma/paraganglioma patients. Endocr Pract. 2017;23:690–704.
PubMed
PubMed Central
Google Scholar
Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med. 2012;367:922–30.
CAS
PubMed
PubMed Central
Google Scholar
Pacak K, Jochmanova I, Prodanov T, Yang C, Merino MJ, Fojo T, et al. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol. 2013;31:1690–8.
PubMed
PubMed Central
Google Scholar
Yang C, Sun MG, Matro J, Huynh TT, Rahimpour S, Prchal JT, et al. Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood. 2013;121:2563–6.
CAS
PubMed
PubMed Central
Google Scholar
Adari H, Lowy DR, Willumsen BM, Der CJ, McCormick F. Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science. 1988;240:518–21.
CAS
PubMed
Google Scholar
Crona J, Verdugo AD, Maharjan R, Stalberg P, Granberg D, Hellman P, et al. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. J Clin Endocrinol Metab. 2013;98:E1266–71.
CAS
PubMed
Google Scholar
Toledo RA, Qin Y, Cheng ZM, Gao Q, Iwata S, Silva GM, et al. Recurrent mutations of chromatin-remodeling genes and kinase receptors in pheochromocytomas and paragangliomas. Clin Cancer Res. 2016;22:2301–10.
CAS
PubMed
Google Scholar
Yang C, Zhuang Z, Fliedner SM, Shankavaram U, Sun MG, Bullova P, et al. Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. J Mol Med (Berl). 2015;93:93–104.
CAS
Google Scholar
Cascon A, Comino-Mendez I, Curras-Freixes M, de Cubas AA, Contreras L, Richter S, et al. Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene. J Natl Cancer Inst. 2015;107:53.
Google Scholar
Fishbein L, Khare S, Wubbenhorst B, DeSloover D, D’Andrea K, Merrill S, et al. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun. 2015;6:6140.
CAS
PubMed
Google Scholar
Pang Y, Gupta G, Yang C, Wang H, Huynh TT, Abdullaev Z, et al. A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2(V617F) positive polycythemia vera: a case report. BMC Cancer. 2018;18:286.
PubMed
PubMed Central
Google Scholar